GIP
The master conductor
GLP-1
+3
Jul 28, 2026
•
7 min read
Retatrutide revolution continues
Weight loss remains the star of the show, but cardiovascular data was underpowered
GLP-1
+3
Jul 2, 2026
•
14 min read
ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron
Orals, Triples, Biologics and even more data from ADA 2026
GLP-1
+4
Jul 1, 2026
•
5 min read
Eloralintide + Tirzepatide = Bariatric Surgery results!
New phase 1b data shows incredible weight loss
GLP-1
+3
Jun 9, 2026
•
12 min read
ADA 2026: Retatrutide Revolution
A paradigm shift in diabetes and obesity arrives!
GLP-1
+6
May 29, 2026
•
10 min read
ADA Conference 2026 Preview
The Super Bowl Conference for diabetes and incretins!
GLP-1
+3
May 21, 2026
•
4 min read
Triumphant! Retatrutide matches bariatric surgery outcomes
Triumph 1 trial led to 19-30% weight loss depending on dose and time on trial.
GLP-1
+3
Mar 19, 2026
•
7 min read
Retatrutide TRANSCENDS diabetes in first phase 3 trial
A shift in what's possible for diabetes and obesity
GLP-1
+2
Mar 11, 2026
•
11 min read
More amylin updates & more tolerable drugs(finally)?
More early trial results from some new players in the obesity medicine space
GLP-1
+5
Dec 16, 2025
•
40 min read
GLP-1 and the kidneys
Incretins are changing the narrative of chronic kidney disease
GLP-1
+3
Dec 11, 2025
•
10 min read
First Retatrutide phase 3 data, a Triumph of Science!
Bariatric surgery in a shot! It might be too effective?! And what's dysesthesia?
GLP-1
+2
Nov 14, 2025
•
31 min read
Obesity Week 2025 Medications
Orforglipron, HRS 9531, MET-097, Eloralintide and Mazdutide, OH MY!
